

## Letter to the Editor

# Does oral vancomycin prophylaxis during systemic antibiotic exposure prevent *Clostridioides difficile* infection relapses? Still in search of an answer

Jeannie D. Chan PharmD, MPH<sup>1,2,3</sup>, Chloe Bryson-Cahn MD<sup>3</sup>, Rupali Jain PharmD<sup>2,3,4</sup>, John B. Lynch MD, MPH<sup>3</sup> and Catherine Liu MD<sup>3</sup>

<sup>1</sup>Department of Pharmacy, Harborview Medical Center, Seattle, Washington, <sup>2</sup>School of Pharmacy, University of Washington, Seattle, Washington, <sup>3</sup>Department of Medicine, Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, Washington and <sup>4</sup>Department of Pharmacy, University of Washington Medical Center, Seattle, Washington

*To the Editor*—*Clostridioides difficile* infection (CDI) represents a significant healthcare challenge, with 10%–30% of patients developing at least 1 recurrent episode, and the risk of relapses increases with each subsequent recurrence.<sup>1</sup> Recurrent CDI is defined by resolution of CDI symptoms while on treatment, followed by symptom reappearance within 2–8 weeks after treatment completion.<sup>1</sup> Exposure to systemic antibiotics in patients with prior CDI has been identified as an independent risk factor associated with CDI recurrence.<sup>1</sup> Despite the lack of robust supporting evidence, secondary prophylaxis with oral vancomycin in patients on systemic antibiotics for infections other than CDI has become common practice.<sup>2–4</sup> We read “Oral vancomycin prophylaxis (OVP) during systemic antibiotic exposure to prevent *Clostridioides difficile* infection relapses” by Caroff et al<sup>4</sup> with great interest. The authors reported that OVP was effective in reducing CDI relapse in patients with incident CDI (1 previous CDI) but not recurrent CDI ( $\geq 2$  CDI episodes).

We applaud the authors for conducting this study and taking into account potential confounders that were not adequately addressed in previous observational studies.<sup>2,3</sup> In a small single-center study (n = 203), Van Hise et al<sup>2</sup> reported that OVP decreased the risk of CDI relapse (odds ratio, 0.12; 95% CI, 0.04–0.4), though they did not differentiate between incident and recurrent CDI with multivariate analysis. Carignan et al<sup>3</sup> demonstrated that the benefit of OVP in preventing CDI relapse was confined to patients with recurrent CDI. Importantly, the significant differences between the Carignan and Caroff investigations make it difficult to draw definitive conclusions, even in these larger-scale multicenter studies (Table 1).

In the Caroff study, the inclusion of hospitalized patients within 150 days of a positive *C. difficile* test did not capture ambulatory CDI cases, which may have explained the reported relapse rate of 9.5%, which is substantially lower than the historical epidemiology of CDI.<sup>1</sup> This low recurrence rate also raises questions about the circulating *C. difficile* strain type. NAP1 (North American

pulsed-field gel electrophoresis type-1) strains are often a predictor of disease severity, recurrence, and increased mortality.<sup>1</sup> The CDI relapse rate of 32.9% reported by Carignan et al may have overlapped with the NAP1 outbreak in Quebec, Canada, in 2002<sup>1</sup> and potentially with NAP1 strains still circulating in the community during their study periods between 2003 to 2011. Because PCR ribotyping was not available in the OVP studies, it is unclear whether NAP1 strain may have contributed to the observed differences in relapse rates. The study populations are somewhat different as well: 50% of the patients were >75 years old in the Carignan study, whereas the average age in the Caroff study was 59–64 years old. In addition to older age being a risk factor for CDI recurrence, older adults may have impaired host defense because neutrophils are less able to phagocytize and kill *C. difficile*.<sup>3</sup> This difference may partially indicate that host factors and humoral immunity play a role in CDI relapses.

Risk stratification of antibiotic class and duration of systemic antibiotic therapy should also be considered when calculating the risk of CDI recurrence given evidence suggesting that cumulative antibiotic exposures (ie, antibiotic dose, number of antibiotics, and days of antibiotic exposure) all appear to be associated with CDI risk.<sup>5</sup> Caroff et al classified antibiotic risk as high, medium, and low, but the median duration of systemic antibiotic exposure was substantially shorter (6 days vs 14 days) than in the Carignan study. This difference led us to question whether a minimum threshold of antibiotic exposures is needed to derive benefit from OVP.

Because oral vancomycin may have deleterious effects to the indigenous microbiota of the colon and may promote colonization with vancomycin resistant *Enterococci* (VRE), carbapenem-resistant *Klebsiella pneumoniae* (KPC), and *E. coli*, it is imperative to carefully weigh the risks and benefits to determine the optimal dose and duration of OVP.<sup>6</sup> The duration of OVP was much shorter (2.3 days vs 7 days) in the Caroff study, and vancomycin dose was not specified. The optimal dose of OVP has yet to be defined, and various dosing regimens for CDI may be used, for example 125 mg 4 times daily in the Carignan’s study and 125–250 mg twice daily in the Van Hise study. With the increasing recognition of vancomycin’s effect on the host microbiome, it seems prudent to define the lowest effective dose of OVP to minimize collateral damage. Because oral vancomycin is not

**Author for correspondence:** Jeannie D. Chan, PharmD, MPH, Harborview Medical Center, 325 Ninth Avenue, Box 359885, Seattle, WA 98104. E-mail: [jdchan@uw.edu](mailto:jdchan@uw.edu)

**Cite this article:** Chan JD, et al. (2019). Does oral vancomycin prophylaxis during systemic antibiotic exposure prevent *Clostridioides difficile* infection relapses? Still in search of an answer. *Infection Control & Hospital Epidemiology*, <https://doi.org/10.1017/ice.2019.192>

**Table 1.** Comparison of Oral Vancomycin Prophylaxis (OVP) During Systemic Antibiotic Exposure in Preventing CDI Relapses

Variable	Carignan et al		Caroff et al	
Study setting	2 hospitals in Quebec, Canada		2 hospitals in Massachusetts, United States	
Study period	2003–2011		2009–2015	
Inclusion criteria	≥18 yo with previous CDI requiring systemic antibiotics within 90 d after CDI diagnosis during a hospital admission or a visit to a hospital outpatient clinic.		Hospitalized patients requiring systemic antibiotics within 150 d after a positive <i>C. difficile</i> test	
Primary end point	CDI recurrence defined as diarrhea with positive <i>C. difficile</i> toxin by toxin assay, enzyme-linked immunoassay, PCR or colitis within 90 d after systemic antibiotic exposure		CDI recurrence defined by either positive <i>C. difficile</i> toxin assay or NAAT within 90 d after systemic antibiotic exposure	
Study population	551 patients 370 initial CDI, 172 recurrent CDI OVP, 227 (41%) No OVP, 324 (59%) Age, 50% with ≥75 yo		760 patients 474 initial CDI, 246 recurrent CDI OVP, 193 (25%); avg age: 64yo No OVP, 567 (75%); avg age: 59yo	
CDI relapse	32.9%		9.5%	
Median antibiotic exposure	14 d (IQR, 10–17 d)		OVP: 5.99 ± 6.29 d No OVP: 5.41 ± 6.65 d	
Concomitant antibiotics	Fluoroquinolones (53%), Carboxy/ureidopenicillins (25%)		71% received high-risk antibiotics (fluoroquinolones, cephalosporins, or carbapenems)	
Median duration of OVP	7 d (IQR, 3–12 d)		2.3 ± 5.8 d	
OVP dose	84% received 125 mg 4 times daily		Dose not specified	
Incident CDI	OVP (n=137)	No OVP (n=242)	OVP (n=118)	No OVP (n=353)
CDI relapse (%)	28 (20.4)	47 (19.4)	10 (8.5)	37 (10.5)
Adjusted ratio (95% CI)	aHR, 0.91 (0.57–1.45)	Referent	aOR, 0.42 (0.19–0.93)	Referent
Recurrent CDI	OVP (n=90)	No OVP (n=82)	OVP (n=64)	No OVP (n=166)
CDI relapse (%)	49 (54.4)	57 (69.5)	7 (10.9)	13 (7.8)
Adjusted ratio (95% CI)	aHR, 0.47 (0.32–0.69)	Referent	aOR, 1.19 (0.42–3.33)	Referent

Note. aHR, adjusted hazard ratio; aOR, adjusted odds ratio; CDI, *Clostridium difficile* infection; CI, confidence intervals; IQR, interquartile range; NAAT, nucleic acid amplification test; OVP, oral vancomycin prophylaxis; PCR, polymerase chain reaction.

systemically absorbed, high colonic vancomycin levels (500–1000 µg/mL) can be achieved with 125 mg 4 times daily, which is several hundred-fold higher than the vancomycin minimum inhibitory concentration (MIC<sub>90</sub>) for *C. difficile*, which typically ranges between 1 and 2 µg/mL.<sup>7,8</sup> Vancomycin 125 mg once daily may be sufficient as secondary prophylaxis for CDI. The duration of OVP is somewhat controversial in light of evidence suggesting that re-establishment of *C. difficile* colonization can occur within a few days to 3 weeks after CDI treatment.<sup>9</sup> Should OVP be stopped at the course completion of systemic antibiotic or be extended to beyond the end of systemic antibiotic, and for how long?

Many unanswered questions remain, and the interpretations of these findings are limited by the inherent nature of retrospective observational studies and conflicting results. The heightened risk period for CDI recurrence is typically within 8 weeks after CDI treatment completion;<sup>1</sup> it is unclear whether case ascertainment between 90 days versus 150 days from a prior CDI contributed to the inconsistent results between these 2 studies. Furthermore, the primary end points of CDI recurrence in existing observational studies are often defined only by positive *C. difficile* testing with or without diarrhea, making it difficult to distinguish between colonization and actual infection in the absence of clinical assessment. Prospective data are needed

to guide the selection criteria of the targeted population with the highest propensity for CDI recurrence who may benefit most from the optimal dose and duration of OVP. We await results from ongoing randomized controlled trials to further inform the clinical utility of OVP as a preventive strategy in reducing the risk of recurrent CDI.<sup>10,11</sup>

**Acknowledgments.** None.

**Financial support.** No financial support was provided relevant to this article.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

## References

- McDonald LC, Gerding DN, Johnson S, *et al*. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect* 2018;66: 987–994.
- Van Hise NW, Bryant AM, Hennessey EK, Crannage AJ, Khoury JA, Manian FA. Efficacy of oral vancomycin in preventing recurrent *Clostridium difficile* infection in patients treated with systemic antimicrobial agents. *Clin Infect Dis* 2016;63:651–653.

3. Carignan A, Poulin S, Martin P, et al. Efficacy of secondary prophylaxis with vancomycin for preventing recurrent *Clostridium difficile* infections. *Am J Gastroenterol* 2016;111:1834–1840.
4. Caroff DA, Menchaca JT, Zhang Zilu, et al. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent *Clostridioides difficile* infection relapses. *Infect Control Hosp Epidemiol* 2019;40:662–667.
5. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of *Clostridium difficile* infection. *Clin Infect Dis* 2011;53:42–48.
6. Lewis BB, Buffie CG, Carter RA, et al. Loss of microbiota-mediated colonization resistance to *Clostridium difficile* infection with oral vancomycin compared to metronidazole. *J Infect Dis* 2015;212:1656–1665.
7. Barlett JG. The case for vancomycin as the preferred drug for treatment of *Clostridium difficile* infection. *Clin Infect Dis* 2008;46:1489–1492.
8. Pepin J. Vancomycin for the treatment of *Clostridium difficile* infection: for whom is this expense bullet really magic? *Clin Infect Dis* 2008;46:1493–1498.
9. Abujamel T, Cadnum JL, Jury LA, et al. Defining the vulnerable period for re-establishment of *Clostridium difficile* colonization after treatment of *C. difficile* infection with oral vancomycin or metronidazole. *PLoS One* 2013;8(10):e76269.
10. Oral vancomycin to prevent recurrent *Clostridium difficile* infection with antibiotics. [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03466502) Identifier: NCT03466502.
11. Efficacy of oral vancomycin prophylaxis for prevention of recurrent *Clostridium difficile* infection. [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03462459) Identifier: NCT03462459.